-
My Account
In App
My Account
BSE Live
Oct 27, 16:01Prev. Close
6587.80
Open Price
6644.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 27, 15:58Prev. Close
6593.00
Open Price
6610.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
6490.00 (6)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 53.00 | 53.00 | 53.09 | 53.09 | 53.09 | |
| Total Share Capital | 53.00 | 53.00 | 53.09 | 53.09 | 53.09 | |
| Reserves and Surplus | 14,842.00 | 13,431.00 | 12,652.33 | 11,638.26 | 9,218.48 | |
| Total Reserves and Surplus | 14,842.00 | 13,431.00 | 12,652.33 | 11,638.26 | 9,218.48 | |
| Total Shareholders Funds | 14,895.00 | 13,484.00 | 12,705.42 | 11,691.35 | 9,271.57 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 509.00 | 582.00 | 537.21 | 421.40 | 338.06 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 37.00 | 30.62 | 26.71 | 25.25 | |
| Total Non-Current Liabilities | 509.00 | 619.00 | 567.83 | 448.11 | 363.31 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2.00 | 0.00 | 0.00 | 0.00 | 0.35 | |
| Trade Payables | 880.00 | 807.00 | 742.64 | 771.30 | 748.78 | |
| Other Current Liabilities | 484.00 | 445.00 | 330.81 | 392.95 | 337.25 | |
| Short Term Provisions | 54.00 | 7.00 | 4.92 | 4.15 | 2.51 | |
| Total Current Liabilities | 1,420.00 | 1,259.00 | 1,078.37 | 1,168.40 | 1,088.89 | |
| Total Capital And Liabilities | 16,824.00 | 15,362.00 | 14,351.62 | 13,307.86 | 10,723.77 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 5,436.00 | 4,733.00 | 4,713.48 | 4,313.48 | 3,694.06 | |
| Intangible Assets | 4.00 | 4.00 | 5.28 | 7.49 | 4.95 | |
| Capital Work-In-Progress | 1,022.00 | 778.00 | 211.88 | 469.93 | 710.62 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 6,462.00 | 5,515.00 | 4,930.64 | 4,790.90 | 4,409.63 | |
| Non-Current Investments | 72.00 | 89.00 | 84.41 | 79.37 | 7.37 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 55.16 | |
| Other Non-Current Assets | 311.00 | 186.00 | 101.12 | 141.63 | 126.30 | |
| Total Non-Current Assets | 6,845.00 | 5,790.00 | 5,116.17 | 5,011.90 | 4,598.46 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 3,033.00 | 2,985.00 | 2,780.45 | 2,644.05 | 2,042.70 | |
| Trade Receivables | 2,855.00 | 2,273.00 | 1,964.30 | 2,569.90 | 1,745.56 | |
| Cash And Cash Equivalents | 3,696.00 | 3,961.00 | 4,187.56 | 2,803.68 | 2,142.01 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 395.00 | 353.00 | 303.14 | 278.33 | 195.04 | |
| Total Current Assets | 9,979.00 | 9,572.00 | 9,235.45 | 8,295.96 | 6,125.31 | |
| Total Assets | 16,824.00 | 15,362.00 | 14,351.62 | 13,307.86 | 10,723.77 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,841.00 | 1,432.00 | 736.98 | 1,259.90 | 1,107.13 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 1,881.00 | 1,537.81 | 1,767.55 | 1,312.68 | |
| Trade/Other Goods | 0.00 | 1,881.00 | 1,537.81 | 1,767.55 | 1,312.68 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 1,867.00 | 35.00 | 33.66 | 27.79 | 21.46 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | 8,154.00 | 6,687.00 | 6,653.68 | 7,844.53 | 5,887.74 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 39.67 | 39.67 | 39.67 | 39.67 | 39.67 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 72.00 | 89.00 | 84.41 | 79.37 | 7.37 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
